Editorial: Treatment for advanced breast cancer with brain metastases

作者
Min Yan,Jin Yang
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:13: 1268702-1268702
标识
DOI:10.3389/fonc.2023.1268702
摘要

With the great revolution of anti-cancer therapy, the prognosis of patients with advanced breast cancer (especially for human epidermal growth factor 2 [HER2]-positive subtype) has been largely improved over decades. More and more patients with brain metastases appear during the long disease course. Brain metastases complicate breast cancer treatment and impact the overall prognosis. In addition to local therapy (radiotherapy or surgery), systemic therapy is becoming attractive in the treatment of patients with metastatic breast cancer and brain metastases. This Research Topic focused on novel agents, new insights into the known regimens, biomarkers for efficacy, and mechanisms of drug resistance in advanced breast cancer with brain metastases. Overall, four articles were collected in this Research Topic.With the emergence of novel drugs, more options are provided for the treatment of brain metastases. Chen et al. published a review to feature currently available systemic therapy strategies and to outline novel drugs and ongoing clinical trials that may be available in the future. Previously studied systemic therapies for patients with HER2positive advanced breast cancer and brain metastases included monoclonal antibodies (trastuzumab and pertuzumab), tyrosine kinase inhibitors (TKIs; lapatinib, neratinib, pyrotinib, and tucatinib), and antibody-drug conjugates (ADCs; trastuzumab emtansine and trastuzumab deruxtecan). For patients with hormone receptor-positive advanced breast cancer and brain metastases, treatments included endocrine therapy (tamoxifen), cyclin-dependent kinases 4/6 inhibitor (abemaciclib), and mammalian target of rapamycin (mTOR) inhibitor (everolimus). For patients with triple-negative advanced breast cancer and brain metastases, treatments included chemotherapy, bevacizumab, and poly (ADP-ribose) polymerase inhibitor (talazoparib).Based on previous literatures, Huo et al. performed a meta-analysis of randomized controlled trials and single-arm clinical studies to analyze the currently most beneficial treatment for patients with HER2-positive breast cancer brain metastases. In randomized controlled trials, trastuzumab deruxtecan significantly improved progression-free survival and overall survival and was superior to other drug regimens.In single-arm studies, the objective response rate was more pronounced for trastuzumab deruxtecan (73.33%) and pyrotinib plus capecitabine (74.58%) regimens. The main adverse events of ADC were nausea and fatigue, while the main AE of small-molecule TKIs and monoclonal antibodies was diarrhea. Regarding biomarkers for efficacy, Freeman et al. examined the association between Karnofsky performance status (KPS) and brain-specific progression-free survival in patients with breast cancer brain metastases treated with surgery and/or radiotherapy.Of 331 patients treated with surgery and/or radiotherapy who had available KPS data, 102 (31%) had KPS ≤60. In a multivariable analysis, KPS ≤60 was the only independent factors of brain-specific progression-free survival (hazard ratio, 1.86; 95% confidence interval, 1.20-2.88).From the abovementioned literatures, we have seen the advance of drug therapy in HER2-positive breast cancer with brain metastases, anti-HER2 ADC trastuzumab deruxtecan and novel TKI pyrotinib have good intracranial and extracranial efficacy.For patients who do not need local therapy immediately at diagnosis of breast cancer brain metastases, such systemic therapies may be used preferentially to prolong the survival of these patients. We hope that the articles published in this Research Topic can help researchers enhance their understanding of treatments and prognostic factors for patients with advanced breast cancer and brain metastases.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dd完成签到,获得积分10
1秒前
大个的应助被muzi采纳,获得10
1秒前
1秒前
乐空思的应助被wjzhai采纳,获得30
1秒前
科研通AI6.2的应助被zhang采纳,获得10
1秒前
Hello的应助被眉书初采纳,获得10
1秒前
wanci的应助被wind采纳,获得10
1秒前
研友_VZG7GZ的应助被有点儿小库采纳,获得10
2秒前
2秒前
2秒前
上官若男的应助被HZN采纳,获得10
3秒前
叶也发布了新的文献求助10
3秒前
要睡觉的锆石完成签到,获得积分10
3秒前
徐丹枫完成签到 ,获得积分10
3秒前
3秒前
3秒前
CodeCraft的应助被背后松采纳,获得10
3秒前
宝儿糯发布了新的文献求助10
3秒前
天天发布了新的文献求助30
4秒前
4秒前
5秒前
JamesPei的应助被未完成的课题采纳,获得10
5秒前
我是谁的应助被chen采纳,获得30
5秒前
5秒前
木子完成签到,获得积分10
6秒前
6秒前
迷路的夏波完成签到,获得积分20
6秒前
米mi发布了新的文献求助10
6秒前
小巧的绝山完成签到,获得积分10
6秒前
源味发布了新的文献求助10
6秒前
7秒前
实验室发布了新的文献求助10
8秒前
Lucas的应助被一笑采纳,获得10
8秒前
luyue9406的应助被机灵垣采纳,获得10
8秒前
8秒前
木子发布了新的文献求助10
8秒前
8秒前
yany发布了新的文献求助10
8秒前
abfs完成签到,获得积分10
8秒前
001发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170142
求助须知:如何正确求助?哪些是违规求助? 9563136
关于积分的说明 21768635
捐赠科研通 7761603
什么是DOI,文献DOI怎么找? 3430600
关于科研通互助平台的介绍 2554420
邀请新用户注册赠送积分活动 2475330